Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound

详细信息    查看全文

• 作者：Glen M. Lo^&lowast ; ; ^&dagger ; ; Hassan Al Zahrani^&lowast ; ; Hyun Jung. Jang^&lowast ; ; Ravi Menezes^&lowast ; ; John Hudson^&Dagger ; ; Peter Burns^&Dagger ; ; Mairé ; ad G. McNamara^§ ; ; ^¶ ; ; Sonja Kandel^&lowast ; ; Korosh Khalili^&lowast ; ; Jennifer Knox^§ ; ; Patrik Rogalla^&lowast ; ; Tae Kyoung Kim^&lowast ; ; ^{taekyoung.kim@uhn.ca" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Dynamic contrast-enhanced ultrasound ; Hepatocellular carcinoma ; Liver Neoplasms ; Axitinib ; Tumor response ; Perfusion
• 刊名：Ultrasound in Medicine & Biology
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：42
• 期：6
• 页码：1303-1311
• 全文大小：1115 K

文摘

This study aimed to evaluate the utility of dynamic contrast-enhanced ultrasound (DCE-US) in measuring early tumor response of advanced hepatocellular carcinoma to axitinib. Twenty patients were enrolled (aged 18–78 y; median 65). DCE-US was performed with bolus injection and infusion/disruption replenishment. Median overall survival was 7.1 mo (1.8–27.3) and progression free survival was 3.6 mo (1.8–17.4). Fifteen patients completed infusion scans and 12 completed bolus scans at 2 wk. Among the perfusion parameters, fractional blood volume at infusion (INF_BV) decreased at 2 wk in 10/15 (16%–81% of baseline, mean 47%) and increased in 5/15 (116%–535%, mean 220%). This was not significantly associated with progression free survival (p = 0.310) or progression at 16 wk (p = 0.849), but was borderline statistically significant (p = 0.050) with overall survival, limited by a small sample size. DCE-US is potentially useful in measuring early tumor response of advanced hepatocellular carcinoma to axitinib, but a larger trial is needed.